Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2025-10-31 00:00:00 ET · period of report 2025-10-29 · accession 0001796226-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-31 | 2025-10-29 | REGN | MURPHY ANDREW J | EVP Research | M - OptEx | $555.67 | +35.0K | 84.1K | +71% | +$19.45M |
| D | 2025-10-31 | 2025-10-29 | REGN | MURPHY ANDREW J | EVP Research | F - Tax | $648.82 | -32.5K | 51.6K | -39% | -$21.08M |
| D | 2025-10-31 | 2025-10-30 | REGN | MURPHY ANDREW J | EVP Research | G - Gift | $0.00 | -1,538 | 50.0K | -3% | $0 |
| D | 2025-10-31 | 2025-10-29 | REGN | MURPHY ANDREW J | EVP Research | M - OptEx | $0.00 | -35.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-29 | M | A | 35,000 | $555.67 | 84,074 | D | — | — | |
| 2 | Common | Common Stock | 2025-10-29 | F | D | 32,490 | $648.82 | 51,584 | D | — | — | |
| 3 | Common | Common Stock | 2025-10-30 | G | D | 1,538 | $0.00 | 50,046 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-10-29 | M | D | 35,000 | $0.00 | 0 | D | $555.67 · — to 2025-12-16 | 35,000 Common Stock | (F1) The stock option award vested in four equal annual installments, commencing one year after the date of grant. |